Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | The benefits of tebentafusp in uveal melanoma

Omid Hamid • 23 Oct 2023
ESMO 2023
Melanoma Skin Cancer Antibodies Checkpoint Inhibitors Tebentafusp

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the future of tebentafusp, a novel immune-mobilising monoclonal TCR against cancer (ImmTAC), for patients with treatment-naïve uveal melanoma. Tebentafusp resulted superior survival in a Phase III trial (NCT03070392), and biomarkers of response such as ctDNA need to be identified in future analyses. The novel ImmTAC additionally has potential as a combination therapy with immune checkpoint inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Omid Hamid

1:54
C-144-01: lifileucel in mucosal melanoma pretreated with ICIs
Omid Hamid • 23 Oct 2023
2:31
The future of BiTEs and ImmTACs in melanoma and beyond
Omid Hamid • 23 Oct 2023
2:01
Elucidating biomarkers of response in the RELATIVITY-047 trial
Omid Hamid • 23 Oct 2023
1:23
Immunotherapy at ASCO 2023: updates in neoadjuvant and adjuvant therapy
Omid Hamid • 5 Jun 2023

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals